Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
2. Azopt
1. 138890-62-7
2. Azopt
3. Al-4862
4. Al 4862
5. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
6. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
7. 138890-50-3
8. Chebi:3176
9. (r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
10. Nsc-760050
11. (+)-4-ethylamino-3,4-dihydro-2-(methoxy)propyl-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
12. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
13. (r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
14. 2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (r)-
15. Brinzolamide [usan]
16. Mfcd08067749
17. Dsstox_cid_25531
18. Dsstox_rid_80934
19. Dsstox_gsid_45531
20. 2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4r)-
21. Bz1
22. 9451z89515
23. (4r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
24. Brinzolamide (brz)
25. Azopt (tn)
26. Brinzolamide (jan/usp/inn)
27. 3znc
28. Ncgc00016979-01
29. Brinzolamide [usan:usp:inn:ban]
30. Unii-9451z89515
31. Brinzolamide- Bio-x
32. Cas-138890-62-7
33. Prestwick0_000365
34. Prestwick1_000365
35. Prestwick2_000365
36. Prestwick3_000365
37. Brinzolamide [mi]
38. Brinzolamide [inn]
39. Brinzolamide [jan]
40. Brinzolamide [vandf]
41. Schembl24636
42. Brinzolamide [mart.]
43. Bspbio_000489
44. Mls002153787
45. Bidd:gt0039
46. Brinzolamide [usp-rs]
47. Brinzolamide [who-dd]
48. Spbio_002410
49. Amy372
50. Bpbio1_000539
51. Chembl220491
52. Gtpl6797
53. Brinzolamide [ema Epar]
54. Dtxsid6045531
55. Bdbm10885
56. Brinzolamide, >=98% (hplc)
57. Brinzolamide [orange Book]
58. Hms1569i11
59. Hms2096i11
60. Hms2234k06
61. Hms3713i11
62. Hms3885i11
63. Brinzolamide [usp Impurity]
64. Azarga Component Brinzolamide
65. Bcp22330
66. Hy-b0588
67. Zinc3953037
68. Brinzolamide [usp Monograph]
69. Tox21_110722
70. S3178
71. Akos005145708
72. Simbrinza Component Brinzolamide
73. Tox21_110722_1
74. Ac-5277
75. Brinzolamide Component Of Azarga
76. Ccg-220365
77. Ccg-222516
78. Db01194
79. Nsc 760050
80. Ncgc00179542-03
81. Ncgc00179542-09
82. Ncgc00179542-10
83. As-35084
84. Bb164262
85. Brinzolamide Component Of Simbrinza
86. Smr001233169
87. Ab00513824
88. B4258
89. Sw197152-3
90. Al4862;al 4862;al-4862
91. C07760
92. D00652
93. Ab00513824_06
94. Q411517
95. Sr-01000838832
96. Q-200751
97. Sr-01000838832-2
98. Brd-k74913225-001-03-3
99. Brinzolamide, United States Pharmacopeia (usp) Reference Standard
100. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide
101. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
102. (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide
103. (4r)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide
104. (5r)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide
105. (r)-3,4-dihydro-4-ethylamino-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
| Molecular Weight | 383.5 g/mol |
|---|---|
| Molecular Formula | C12H21N3O5S3 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 383.06433430 g/mol |
| Monoisotopic Mass | 383.06433430 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 598 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Azopt |
| PubMed Health | Brinzolamide (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use. Brinzolamide is described chemically as: (R)-(+)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno [3,2-e]-1... |
| Active Ingredient | Brinzolamide |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Azopt |
| PubMed Health | Brinzolamide (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use. Brinzolamide is described chemically as: (R)-(+)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno [3,2-e]-1... |
| Active Ingredient | Brinzolamide |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon Pharms |
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
FDA Label
Azopt is indicated to decrease elevated intraocular pressure in:
- ocular hypertension;
- open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Used in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinzolamide can decrease intraocular pressure by approximately 16-19% in patients with elevated intraocular pressure.
Carbonic Anhydrase Inhibitors
A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)
S01EC04
S01EC04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EC - Carbonic anhydrase inhibitors
S01EC04 - Brinzolamide
Absorption
Absorbed into systemic circulation following topical ocular application
Ophthalmic
111 days
Brinzolamide is a highly specific inhibitor of CA-II, which is the main CA isoenzyme involved in the secretion of aqueous humor. Inhibition of CA in the ciliary process of the eye slows the formation of bicarbonate, and reduces sodium and fluid transport. This results in a reduction in the rate of aqueous humor secretion and the intraocular pressure. Brinzolamide is absorbed systemically following topical ocular administration. Since it has a high affinity for CA-II, brinzolamide binds extensively to red blood cells, where CA-II is primarily found. As sufficient CA-II activity remains, adverse effects resulting from the systemic inhibition of CA by brinzolamide are not observed. The metabolite N-desethyl brinzolamide is also formed. This metabolite binds to CA and accumulates in red blood cells as well. In the presence of brinzolamide, the metabolite binds mainly to carbonic anhydrase I (CA-I).
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Curia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Chewable & Orodispersible Aids
Direct Compression
Taste Masking
Parenteral
Topical
Solubilizers
Co-Processed Excipients
Thickeners and Stabilizers
Granulation
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Emulsifying Agents
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Brinzolamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brinzolamide, including repackagers and relabelers. The FDA regulates Brinzolamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brinzolamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Brinzolamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Brinzolamide supplier is an individual or a company that provides Brinzolamide active pharmaceutical ingredient (API) or Brinzolamide finished formulations upon request. The Brinzolamide suppliers may include Brinzolamide API manufacturers, exporters, distributors and traders.
click here to find a list of Brinzolamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Brinzolamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Brinzolamide active pharmaceutical ingredient (API) in detail. Different forms of Brinzolamide DMFs exist exist since differing nations have different regulations, such as Brinzolamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Brinzolamide DMF submitted to regulatory agencies in the US is known as a USDMF. Brinzolamide USDMF includes data on Brinzolamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Brinzolamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Brinzolamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Brinzolamide Drug Master File in Japan (Brinzolamide JDMF) empowers Brinzolamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Brinzolamide JDMF during the approval evaluation for pharmaceutical products. At the time of Brinzolamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Brinzolamide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Brinzolamide Drug Master File in Korea (Brinzolamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Brinzolamide. The MFDS reviews the Brinzolamide KDMF as part of the drug registration process and uses the information provided in the Brinzolamide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Brinzolamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Brinzolamide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Brinzolamide suppliers with KDMF on PharmaCompass.
A Brinzolamide written confirmation (Brinzolamide WC) is an official document issued by a regulatory agency to a Brinzolamide manufacturer, verifying that the manufacturing facility of a Brinzolamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Brinzolamide APIs or Brinzolamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Brinzolamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Brinzolamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Brinzolamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Brinzolamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Brinzolamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Brinzolamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Brinzolamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Brinzolamide suppliers with NDC on PharmaCompass.
Brinzolamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brinzolamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brinzolamide GMP manufacturer or Brinzolamide GMP API supplier for your needs.
A Brinzolamide CoA (Certificate of Analysis) is a formal document that attests to Brinzolamide's compliance with Brinzolamide specifications and serves as a tool for batch-level quality control.
Brinzolamide CoA mostly includes findings from lab analyses of a specific batch. For each Brinzolamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brinzolamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Brinzolamide EP), Brinzolamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brinzolamide USP).
LOOKING FOR A SUPPLIER?
